Cargando…

AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC

BACKGROUND: Non-small cell lung cancer (NSCLC) is a malignancy with considerable morbidity and mortality. Abnormal metabolism is a hallmark of cancer; however, the mechanism of glycolysis regulation in NSCLC progression is not completely understood. Recent studies suggest that some dysregulated long...

Descripción completa

Detalles Bibliográficos
Autores principales: Hua, Qian, Wang, Dongliang, Zhao, Lin, Hong, Zhihui, Ni, Kairu, Shi, Yizhen, Liu, Zengli, Mi, Baoming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502354/
https://www.ncbi.nlm.nih.gov/pubmed/34627260
http://dx.doi.org/10.1186/s12935-021-02232-z
_version_ 1784580879715139584
author Hua, Qian
Wang, Dongliang
Zhao, Lin
Hong, Zhihui
Ni, Kairu
Shi, Yizhen
Liu, Zengli
Mi, Baoming
author_facet Hua, Qian
Wang, Dongliang
Zhao, Lin
Hong, Zhihui
Ni, Kairu
Shi, Yizhen
Liu, Zengli
Mi, Baoming
author_sort Hua, Qian
collection PubMed
description BACKGROUND: Non-small cell lung cancer (NSCLC) is a malignancy with considerable morbidity and mortality. Abnormal metabolism is a hallmark of cancer; however, the mechanism of glycolysis regulation in NSCLC progression is not completely understood. Recent studies suggest that some dysregulated long non-coding RNAs (lncRNAs) play important roles in tumor metabolic reprogramming. METHODS: To identify glycolysis-associated-lncRNAs in NSCLC, we compared RNA-sequencing results between high (18)F-fluorodeoxyglucose (FDG)-uptake NSCLC tissues and paired paratumor tissues. The transcript abundance of AL355338 in 80 pairs of clinical samples was evaluated by quantitative real-time PCR assay and fluorescence in situ hybridization. The biological role of AL355338 on NSCLC cells were evaluated by functional experiments in vitro and in vivo. Moreover, RNA pull-down, mass spectrometry and RNA immunoprecipitation (RIP) assays were used to identify the protein interacted with AL355338. Co-immunoprecipitation, in situ proximity ligation assays and western blotting were applied to define the potential downstream pathways of AL355338. RESULTS: AL355338 was an upregulated glycolysis-associated lncRNA in NSCLC. Functional assays revealed that AL355338 was critical for promoting aerobic glycolysis and NSCLC progression. Mechanistic investigations showed that AL355338 directly bound with alpha-enolase (ENO1) and enhanced the protein’s stability by modulating its degradation and ubiquitination. A positive correlation was observed between AL355338 and ENO1 in NSCLC, and ENO1 was subsequently confirmed to be responsible for the oncogenic role of AL355338. Furthermore, AL355338 was capable of modulating ENO1/EGFR complex interaction and further activating EGFR-AKT signaling. CONCLUSIONS: This study indicates that AL355338 confers an aggressive phenotype to NSCLC, and targeting it might be an effective therapeutic strategy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02232-z.
format Online
Article
Text
id pubmed-8502354
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85023542021-10-20 AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC Hua, Qian Wang, Dongliang Zhao, Lin Hong, Zhihui Ni, Kairu Shi, Yizhen Liu, Zengli Mi, Baoming Cancer Cell Int Primary Research BACKGROUND: Non-small cell lung cancer (NSCLC) is a malignancy with considerable morbidity and mortality. Abnormal metabolism is a hallmark of cancer; however, the mechanism of glycolysis regulation in NSCLC progression is not completely understood. Recent studies suggest that some dysregulated long non-coding RNAs (lncRNAs) play important roles in tumor metabolic reprogramming. METHODS: To identify glycolysis-associated-lncRNAs in NSCLC, we compared RNA-sequencing results between high (18)F-fluorodeoxyglucose (FDG)-uptake NSCLC tissues and paired paratumor tissues. The transcript abundance of AL355338 in 80 pairs of clinical samples was evaluated by quantitative real-time PCR assay and fluorescence in situ hybridization. The biological role of AL355338 on NSCLC cells were evaluated by functional experiments in vitro and in vivo. Moreover, RNA pull-down, mass spectrometry and RNA immunoprecipitation (RIP) assays were used to identify the protein interacted with AL355338. Co-immunoprecipitation, in situ proximity ligation assays and western blotting were applied to define the potential downstream pathways of AL355338. RESULTS: AL355338 was an upregulated glycolysis-associated lncRNA in NSCLC. Functional assays revealed that AL355338 was critical for promoting aerobic glycolysis and NSCLC progression. Mechanistic investigations showed that AL355338 directly bound with alpha-enolase (ENO1) and enhanced the protein’s stability by modulating its degradation and ubiquitination. A positive correlation was observed between AL355338 and ENO1 in NSCLC, and ENO1 was subsequently confirmed to be responsible for the oncogenic role of AL355338. Furthermore, AL355338 was capable of modulating ENO1/EGFR complex interaction and further activating EGFR-AKT signaling. CONCLUSIONS: This study indicates that AL355338 confers an aggressive phenotype to NSCLC, and targeting it might be an effective therapeutic strategy. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12935-021-02232-z. BioMed Central 2021-10-09 /pmc/articles/PMC8502354/ /pubmed/34627260 http://dx.doi.org/10.1186/s12935-021-02232-z Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Primary Research
Hua, Qian
Wang, Dongliang
Zhao, Lin
Hong, Zhihui
Ni, Kairu
Shi, Yizhen
Liu, Zengli
Mi, Baoming
AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
title AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
title_full AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
title_fullStr AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
title_full_unstemmed AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
title_short AL355338 acts as an oncogenic lncRNA by interacting with protein ENO1 to regulate EGFR/AKT pathway in NSCLC
title_sort al355338 acts as an oncogenic lncrna by interacting with protein eno1 to regulate egfr/akt pathway in nsclc
topic Primary Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502354/
https://www.ncbi.nlm.nih.gov/pubmed/34627260
http://dx.doi.org/10.1186/s12935-021-02232-z
work_keys_str_mv AT huaqian al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT wangdongliang al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT zhaolin al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT hongzhihui al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT nikairu al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT shiyizhen al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT liuzengli al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc
AT mibaoming al355338actsasanoncogeniclncrnabyinteractingwithproteineno1toregulateegfraktpathwayinnsclc